Catalyst Pharmaceuticals, Inc. (CPRX)

Market Cap	2.62B
Revenue (ttm)	578.20M
Net Income (ttm)	217.56M
Shares Out	122.39M
EPS (ttm)	1.71
PE Ratio	12.52
Forward PE	14.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,942,422
Open	21.27
Previous Close	20.99
Day's Range	20.66 - 22.19
52-Week Range	19.05 - 26.58
Beta	0.69
Analysts	Strong Buy
Price Target	33.17 (+55.07%)
Earnings Date	Nov 5, 2025

About CPRX

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2006
• Employees: 181
• Stock Exchange: NASDAQ
• Ticker Symbol: CPRX
• Website: https://catalystpharma.com

Financial Performance

In 2024, Catalyst Pharmaceuticals's revenue was $491.73 million, an increase of 23.49% compared to the previous year's $398.20 million. Earnings were $163.89 million, an increase of 129.50%.

Analyst Summary

According to 6 analysts, the average rating for CPRX stock is "Strong Buy." The 12-month stock price target is $33.17, which is an increase of 55.07% from the latest price.

Price Target

$33.17

(55.07% upside)

Analyst Consensus: Strong Buy